Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incannex Healthcare Inc IXHL

Healthcare
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety... see more

Recent & Breaking News (NDAQ:IXHL)

Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea ('OSA')

GlobeNewswire November 17, 2022

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

GlobeNewswire October 28, 2022

Incannex Completes Dosing in Phase 1 Clinical Trial to Assess Multi-Use, Anti-Inflammatory Drug IHL-675A; Proceeds to Phase 2 Clinical Trials

GlobeNewswire October 13, 2022

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

GlobeNewswire October 11, 2022

Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 8, 2022

Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors

GlobeNewswire August 17, 2022

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

PR Newswire August 2, 2022

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

PR Newswire July 27, 2022

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

PR Newswire July 21, 2022

Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference

PR Newswire June 27, 2022

Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea

PR Newswire June 3, 2022

Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea

PR Newswire May 17, 2022

Incannex Completes Share Sale and Purchase Agreement to Wholly Acquire APIRx Pharmaceuticals USA, LLC

PR Newswire May 12, 2022

Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion

PR Newswire May 10, 2022

Quarterly Activities Report and Appendix 4C Cash Flow Statement

PR Newswire April 28, 2022

Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M

PR Newswire April 28, 2022

Incannex to Acquire APIRx Pharmaceuticals USA, LLC

PR Newswire March 24, 2022

Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies

PR Newswire March 10, 2022

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics

PR Newswire March 3, 2022

Incannex Completes Listing of American Depositary Shares on Nasdaq; Rings Nasdaq Closing Bell

PR Newswire February 28, 2022